(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Acute Respiratory Distress Syndrome pipeline constitutes 50+ key companies continuously working towards developing 50+ Acute Respiratory Distress Syndrome treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Acute Respiratory Distress Syndrome Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
“Acute Respiratory Distress Syndrome Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Acute Respiratory Distress Syndrome Market.
Some of the key takeaways from the Acute Respiratory Distress Syndrome Pipeline Report:
-
Companies across the globe are diligently working toward developing novel Acute Respiratory Distress Syndrome treatment therapies with a considerable amount of success over the years.
-
Acute Respiratory Distress Syndrome companies working in the treatment market are RS BioTherapeutics, AVM Biotechnology, Cynata Therapeutics, Vasomune Therapeutics, Aqualung Therapeutics, Staidson (Beijing) Biopharmaceuticals, GEn1E Lifesciences, Cartesian Therapeutics, BioAegis Therapeutics Inc., Direct Biologics, LLC, Dompé Farmaceutici S.p.A, Pharmazz, Inc., Aqualung Therapeutics Corp., MedRegen LLC, Thiogenesis Therapeutics, Inc., Hospital Universitario Infanta Leonor, Guy’s and St Thomas’ NHS Foundation Trust, Fujian Medical University, Biotest, Aerogen Pharma Limited, MediciNova, NorthShore University HealthSystem, AstraZeneca, Asklepion Pharmaceuticals, and others, are developing therapies for the Acute Respiratory Distress Syndrome treatment
-
Emerging Acute Respiratory Distress Syndrome therapies in the different phases of clinical trials are- RSBT-001, AVM0703, CYP 001, AV 001, ALT-100, STSA-1002, GEn-1124, Descartes 30, Rhu-pGSN, ExoFlo, Reparixin 600mg, Centhaquine, ALT-100 mAb, MRG-001, TTI-0102, Dexamethasone, Isoflurane, Pirfenidone/Placebo, Trimodulin, AeroFact, Ibudilast, Poractant Alfa, Tozorakimab, L-citrulline, and others are expected to have a significant impact on the Acute Respiratory Distress Syndrome market in the coming years.
-
In May 2025, BioAegis Therapeutics, a leading biotech firm specializing in innovative treatments for acute and chronic inflammatory conditions, has begun patient recruitment in all 13 targeted countries for its Phase 2 trial of rhu-pGSN to treat ARDS (NCT05947955). The company’s pipeline centers on gelsolin (GSN), a highly conserved and essential immune-regulating protein that manages dysfunctional inflammation while preserving normal immune function.
-
In February 2025, Bonus Biogroup (TASE: BONS), a late-stage biotech firm specializing in immunomodulatory and regenerative mesenchymal stromal cell (MSC) therapies, has announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to initiate a Phase III clinical trial in the U.S. The study will assess the safety and effectiveness of MesenCure™—an allogeneic cell therapy composed of enhanced MSCs derived from adipose tissue—for the treatment of respiratory distress in severely ill, hospitalized patients suffering from COVID-19-related pneumonia. MesenCure is designed to address inflammation and tissue damage.
-
In January 2025, InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company developing anti-inflammatory therapies targeting the complement system, has announced that the European Commission (EC) has granted marketing authorization under exceptional circumstances for GOHIBIC® (vilobelimab). This approval covers the treatment of adult patients with SARS-CoV-2-induced acute respiratory distress syndrome (ARDS) who are receiving systemic corticosteroids as part of standard care and require invasive mechanical ventilation (IMV), with or without extracorporeal membrane oxygenation (ECMO). GOHIBIC is the first and only approved therapy in the EU specifically for SARS-CoV-2-related ARDS.
-
In November 2024, InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical firm specializing in anti-inflammatory treatments targeting the complement system, announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive recommendation for the marketing authorization of GOHIBIC (vilobelimab). The recommendation supports its use under exceptional circumstances for adult patients with SARS-CoV-2-induced acute respiratory distress syndrome (ARDS) who are receiving systemic corticosteroids and invasive mechanical ventilation (IMV), with or without ECMO. The company anticipates a final decision from the European Commission within 67 days.
-
In October 2024, BioAegis Therapeutics, an innovative biotech company focused on developing therapies for inflammatory diseases, is excited to announce the enrollment of the first patient in its Phase 2 study of rhu-pGSN for the treatment of Acute Respiratory Distress Syndrome (ARDS) (NCT05947955).
Acute Respiratory Distress Syndrome Overview
Acute Respiratory Distress Syndrome (ARDS) is a severe lung condition where fluid builds up in the air sacs (alveoli), preventing enough oxygen from reaching the bloodstream. It often occurs in critically ill patients or as a response to trauma, pneumonia, sepsis, or inhalation injuries. ARDS causes rapid breathing, shortness of breath, and low blood oxygen levels, often requiring mechanical ventilation. It is life-threatening and needs immediate intensive care.
Get a Free Sample PDF Report to know more about Acute Respiratory Distress Syndrome Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/acute-respiratory-distress-syndrome-pipeline-insight
Emerging Acute Respiratory Distress Syndrome Drugs Under Different Phases of Clinical Development Include:
-
RSBT-001: RS BioTherapeutics
-
AVM0703: AVM Biotechnology
-
CYP 001: Cynata Therapeutics
-
AV 001: Vasomune Therapeutics
-
ALT-100: Aqualung Therapeutics
-
STSA-1002: Staidson (Beijing) Biopharmaceuticals
-
GEn-1124: GEn1E Lifesciences
-
Descartes 30: Cartesian Therapeutics
-
Rhu-pGSN: BioAegis Therapeutics Inc.
-
ExoFlo: Direct Biologics, LLC
-
Reparixin 600mg: Dompé Farmaceutici S.p.A
-
Centhaquine: Pharmazz, Inc.
-
ALT-100 mAb: Aqualung Therapeutics Corp.
-
MRG-001: MedRegen LLC
-
TTI-0102: Thiogenesis Therapeutics, Inc.
-
Dexamethasone: Hospital Universitario Infanta Leonor
-
Isoflurane: Guy’s and St Thomas’ NHS Foundation Trust
-
Pirfenidone/Placebo: Fujian Medical University
-
Trimodulin: Biotest
-
AeroFact: Aerogen Pharma Limited
-
Ibudilast: MediciNova
-
Poractant Alfa: NorthShore University HealthSystem
-
Tozorakimab: AstraZeneca
-
L-citrulline: Asklepion Pharmaceuticals
Acute Respiratory Distress Syndrome Route of Administration
Acute Respiratory Distress Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
-
Oral
-
Parenteral
-
Intravitreal
-
Subretinal
-
Topical
-
Molecule Type
Acute Respiratory Distress Syndrome Molecule Type
Acute Respiratory Distress Syndrome Products have been categorized under various Molecule types, such as
-
Monoclonal Antibody
-
Peptides
-
Polymer
-
Small molecule
-
Gene therapy
-
Product Type
Acute Respiratory Distress Syndrome Pipeline Therapeutics Assessment
-
Acute Respiratory Distress Syndrome Assessment by Product Type
-
Acute Respiratory Distress Syndrome By Stage and Product Type
-
Acute Respiratory Distress Syndrome Assessment by Route of Administration
-
Acute Respiratory Distress Syndrome By Stage and Route of Administration
-
Acute Respiratory Distress Syndrome Assessment by Molecule Type
-
Acute Respiratory Distress Syndrome by Stage and Molecule Type
DelveInsight’s Acute Respiratory Distress Syndrome Report covers around 50+ products under different phases of clinical development like
-
Late-stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I)
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
-
Route of Administration
Further Acute Respiratory Distress Syndrome product details are provided in the report. Download the Acute Respiratory Distress Syndrome pipeline report to learn more about the emerging Acute Respiratory Distress Syndrome therapies
Some of the key companies in the Acute Respiratory Distress Syndrome Therapeutics Market include:
Key companies developing therapies for Acute Respiratory Distress Syndrome are – Fisher & Paykel Healthcare Limited, NRx Pharmaceuticals, Inc., Faron Pharmaceuticals, BioMarck Pharmaceuticals, GE Healthcare, Hamilton Company, Athersys, United Therapeutics, Apeptico Forschung, HEALIOS K.K, Dragerwerk AG & Co. KGaA, ALung Technologies, Inc ( LivaNova PLC), and others.
Acute Respiratory Distress Syndrome Pipeline Analysis:
The Acute Respiratory Distress Syndrome pipeline report provides insights into
-
The report provides detailed insights about companies that are developing therapies for the treatment of Acute Respiratory Distress Syndrome with aggregate therapies developed by each company for the same.
-
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Acute Respiratory Distress Syndrome Treatment.
-
Acute Respiratory Distress Syndrome key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
Acute Respiratory Distress Syndrome Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Acute Respiratory Distress Syndrome market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Acute Respiratory Distress Syndrome drugs and therapies
Acute Respiratory Distress Syndrome Pipeline Market Drivers
Acute Respiratory Distress Syndrome Pipeline Market Barriers
Scope of Acute Respiratory Distress Syndrome Pipeline Drug Insight
-
Coverage: Global
-
Key Acute Respiratory Distress Syndrome Companies: RS BioTherapeutics, AVM Biotechnology, Cynata Therapeutics, Vasomune Therapeutics, Aqualung Therapeutics, Staidson (Beijing) Biopharmaceuticals, GEn1E Lifesciences, Cartesian Therapeutics, BioAegis Therapeutics Inc., Direct Biologics, LLC, Dompé Farmaceutici S.p.A, Pharmazz, Inc., Aqualung Therapeutics Corp., MedRegen LLC, Thiogenesis Therapeutics, Inc., Hospital Universitario Infanta Leonor, Guy’s and St Thomas’ NHS Foundation Trust, Fujian Medical University, Biotest, Aerogen Pharma Limited, MediciNova, NorthShore University HealthSystem, AstraZeneca, Asklepion Pharmaceuticals, and others
-
Key Acute Respiratory Distress Syndrome Therapies: RSBT-001, AVM0703, CYP 001, AV 001, ALT-100, STSA-1002, GEn-1124, Descartes 30, Rhu-pGSN, ExoFlo, Reparixin 600mg, Centhaquine, ALT-100 mAb, MRG-001, TTI-0102, Dexamethasone, Isoflurane, Pirfenidone/Placebo, Trimodulin, AeroFact, Ibudilast, Poractant Alfa, Tozorakimab, L-citrulline, and others
-
Acute Respiratory Distress Syndrome Therapeutic Assessment: Acute Respiratory Distress Syndrome current marketed and Acute Respiratory Distress Syndrome emerging therapies
-
Acute Respiratory Distress Syndrome Market Dynamics: Acute Respiratory Distress Syndrome market drivers and Acute Respiratory Distress Syndrome market barriers
Request for Sample PDF Report for Acute Respiratory Distress Syndrome Pipeline Assessment and clinical trials
Table of Contents
1. Acute Respiratory Distress Syndrome Report Introduction
2. Acute Respiratory Distress Syndrome Executive Summary
3. Acute Respiratory Distress Syndrome Overview
4. Acute Respiratory Distress Syndrome- Analytical Perspective In-depth Commercial Assessment
5. Acute Respiratory Distress Syndrome Pipeline Therapeutics
6. Acute Respiratory Distress Syndrome Late Stage Products (Phase II/III)
7. Acute Respiratory Distress Syndrome Mid Stage Products (Phase II)
8. Acute Respiratory Distress Syndrome Early Stage Products (Phase I)
9. Acute Respiratory Distress Syndrome Preclinical Stage Products
10. Acute Respiratory Distress Syndrome Therapeutics Assessment
11. Acute Respiratory Distress Syndrome Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Acute Respiratory Distress Syndrome Key Companies
14. Acute Respiratory Distress Syndrome Key Products
15. Acute Respiratory Distress Syndrome Unmet Needs
16 . Acute Respiratory Distress Syndrome Market Drivers and Barriers
17. Acute Respiratory Distress Syndrome Future Perspectives and Conclusion
18. Acute Respiratory Distress Syndrome Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: Acute Respiratory Distress Syndrome Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | RS BioTherapeutics, AVM Biotech, Cynata Therapeutics
Troncale holds a J.D. in Law and is an esteemed business pioneer. His past roles include serving as vice president at California Republic Bank, and he was the founder and president of Nano Banc, where his team of six achieved $1.3 billion in deposits from commercial clients in one year. He is the creator of the Merged Podcast, which identifies new innovative technologies. Troncale is also the creator of Atlas, a leading-edge banking security system.
